U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Modified Factor Xa Polypeptides to Recover Clotting Activity in Subjects Treated with Direct Oral Anticoagulants (DOACs)
  1. Licensing and Collaboration Opportunities

Modified Factor Xa Polypeptides to Recover Clotting Activity in Subjects Treated with Direct Oral Anticoagulants (DOACs)

 Download the Abstract (PDF - 120KB)

Technology Summary

Direct oral anticoagulants (DOACs) are used to treat patients with thromboembolic or clotting disorders, including those at risk for blood clots due to deep vein thrombosis, strokes, heart attacks, and pulmonary embolism. Patients receiving DOACs are at risk of excessive bleeding during accidents or emergency surgeries and require a means for reestablishing blood clotting. This technology may provide a means for directly reestablishing clotting in people receiving DOACs.

DOACs act by directly binding an enzyme that plays a critical role in coagulation, factor Xa, blocking coagulant activity. In emergency situations, the current strategy for reversing the anticoagulant activity of DOACs is to is to provide a decoy variant factor Xa receptor for it to bind instead or native factor Xa restoring its coagulation activity. This invention provides a novel alternate strategy for directly reestablishing factor Xa coagulation by using a variant factor Xa polypeptide that retains coagulant activity in the presence of DOACs.

Potential Commercial Applications Competitive Advantages
  •  Reestablish clotting activity in people receiving Direct Acting Anticoagulants
  •  Treatment of patients in emergency situations
  •  Directly reestablishes clotting activity in people taking DOACs 
  •  Improved safety profile enabled by smaller therapeutic dosage requirements

Development Stage: Proof-of-concept, In vivo animal data

Inventors: Zuben Sauna, Wojciech Jankowski, and Nancy Hernandez

Publications: NA

Intellectual Property: U.S. provisional application 63/339,230 was filed May 6, 2022

Product Area: Biologics, Direct Acting Anticoagulants, DOACs, Thromboembolic Disease, Bleeding Disorders

FDA Reference No: E-2022-003

Licensing Contact:
FDA Technology Transfer Program
Email: FDAInventionLicensing@fda.hhs.gov

Back to Top